Bulk RNA-seq expression profiles were obtained from 1,440 publicly available samples from 11 datasets across 6 cancer types37,38,39,40(seeSTAR Methods) and scored for a 15-gene Ly6E(hi)-signature (NeutIFN-15) (top) or a previously published 6-gene IFNγ-signature41(bottom). A heatmap of median, normalized enrichment scores for each dataset is shown and significant differences between groups were tested (NR vs. R). Samples were taken either pre-treatment (PRE) or post-treatment (POST). Raw data are available inFigure S10. BLCA = urothelial bladder cancer; GBM = glioblastoma multiforme; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; SKCM = skin cutaneous melanoma; STAD = stomach adenocarcinoma. Significance was assessed by means of a one-way Mann-Whitney test (NS, p > 0.01;*, p < 0.01;**, p < 0.001,***, p < 0.0001).
